 Nature.com | Biobusiness Briefs: Trial watch: Dual-acting combination meets heart failure ... Nature.com Novartis has announced positive results from the Phase II PARAMOUNT trial of its first-in-class angiotensin receptor neprilysin inhibitor combination, LCZ696, in patients with heart failure with preserved ejection fraction (HFPEF). The dual-acting ... |
